{
    "clinical_study": {
        "@rank": "18131", 
        "arm_group": [
            {
                "arm_group_label": "Dexamethasone Punctum Plug", 
                "arm_group_type": "Active Comparator", 
                "description": "Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days"
            }, 
            {
                "arm_group_label": "Placebo Vehicle Punctum Plug", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo punctum plug insertion"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone)\n      depot when placed in the canaliculus of the eyelid for  the treatment of ocular inflammation\n      and pain in subjects who have undergone cataract extraction with intra-ocular lens\n      implantation."
        }, 
        "brief_title": "Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Ocular Inflammation and Pain", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Cataract", 
                "Capsule Opacification"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has provided written informed consent, approved by the appropriate   institutional\n             review board; and is able to comply with study requirements and visit schedule\n\n          -  Is greater than or equal to 21 years of age\n\n          -  Has a cataract and is expected to undergo clear corneal cataract surgery with\n             phacoemulsification and implantation of a posterior chamber intraocular lens\n\n        Exclusion Criteria:\n\n          -  Any intraocular inflammation in the study eye present during the screening slit lamp\n             examination\n\n          -  Score greater than \"0\" on the Ocular Pain Assessment at Screening\n\n          -  Compromised immune system or an autoimmune disease that in the opinion of the\n             Investigator could affect the quality of the ocular surface"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666210", 
            "org_study_id": "OTX-12-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dexamethasone Punctum Plug", 
                "description": "Sustained and tapered release of dexamethasone from hydrogel punctum plug", 
                "intervention_name": "OTX-DP (Dexamethasone punctum plug)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Vehicle Punctum Plug", 
                "description": "Hydrogel punctum plug without dexamethasone", 
                "intervention_name": "Placebo Vehicle Punctum Plug", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Hoffman Estates", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60169"
                }, 
                "name": "Chicago Cornea Consultants, Ltd."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase II Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Absence of cells in anterior chamber of study eye", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }, 
            {
                "measure": "Absence of pain in the study eye", 
                "safety_issue": "No", 
                "time_frame": "Day 8"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666210"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "37 days"
        }, 
        "source": "Ocular Therapeutix, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ocular Therapeutix, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}